AG˹ٷ

STOCK TITAN

Bespoke Extracts, Inc. Announces Financial Results and Strategic Rebranding for the First Quarter Ended March 31, 2025

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Bespoke Extracts (OTCQB: BSPK) reported its Q1 2025 financial results and strategic rebranding initiatives. The company achieved revenue of $263,159, a 1% increase from Q1 2024, despite an 8.8% contraction in Colorado's cannabis market. Gross profit improved to $110,779 from $102,581 year-over-year, while net loss decreased to $260,521 from $314,118.

The company successfully rebranded as The Joint Company (TJC), launching two new products - Doobskis and Dutch Blunts. Operational improvements led to a 32% increase in daily pre-roll production compared to Q1 2024. For Q2 2025, the company projects revenue to exceed $385,000, significantly higher than Q2 2024's $278,163.

Despite these improvements, the company faces financial challenges with a total stockholders' deficit of $2,334,200 as of March 31, 2025, and current liabilities of $1,241,535 against current assets of $123,120.

[ "Revenue increased 1% YoY to $263,159 despite market contraction", "Gross profit improved to $110,779 from $102,581 YoY", "Operating expenses reduced by 12.2% to $356,117", "Net loss decreased to $260,521 from $314,118 YoY", "Daily pre-roll production increased by 32%", "Q2 2025 revenue projected to exceed $385,000, significantly higher than Q2 2024's $278,163" ]

Bespoke Extracts (OTCQB: BSPK) ha comunicato i risultati finanziari del primo trimestre 2025 e le iniziative di rebranding strategico. L’azienda ha raggiunto un fatturato di 263.159 dollari, con un aumento dell�1% rispetto al primo trimestre 2024, nonostante una contrazione dell�8,8% del mercato della cannabis in Colorado. Il profitto lordo è cresciuto a 110.779 dollari rispetto a 102.581 dollari dell’anno precedente, mentre la perdita netta è diminuita a 260.521 dollari da 314.118 dollari.

La società ha completato con successo il rebranding diventando The Joint Company (TJC) e ha lanciato due nuovi prodotti: Doobskis e Dutch Blunts. I miglioramenti operativi hanno portato a un aumento del 32% nella produzione giornaliera di pre-roll rispetto al primo trimestre 2024. Per il secondo trimestre 2025, la società prevede un fatturato superiore a 385.000 dollari, ben al di sopra dei 278.163 dollari del secondo trimestre 2024.

Nonostante questi progressi, l’azienda affronta sfide finanziarie con un deficit totale per gli azionisti di 2.334.200 dollari al 31 marzo 2025 e passività correnti di 1.241.535 dollari rispetto ad attività correnti di 123.120 dollari.

Bespoke Extracts (OTCQB: BSPK) informó sus resultados financieros del primer trimestre de 2025 e iniciativas estratégicas de rebranding. La compañía alcanzó unos ingresos de 263,159 dólares, un aumento del 1% respecto al primer trimestre de 2024, a pesar de una contracción del 8.8% en el mercado de cannabis de Colorado. La ganancia bruta mejoró a 110,779 dólares desde 102,581 dólares interanuales, mientras que la pérdida neta disminuyó a 260,521 dólares desde 314,118 dólares.

La empresa se rebrandó con éxito como The Joint Company (TJC) y lanzó dos nuevos productos: Doobskis y Dutch Blunts. Las mejoras operativas llevaron a un aumento del 32% en la producción diaria de pre-rolls en comparación con el primer trimestre de 2024. Para el segundo trimestre de 2025, la compañía proyecta ingresos superiores a 385,000 dólares, significativamente más altos que los 278,163 dólares del segundo trimestre de 2024.

A pesar de estas mejoras, la empresa enfrenta desafíos financieros con un déficit total para los accionistas de 2,334,200 dólares al 31 de marzo de 2025 y pasivos corrientes de 1,241,535 dólares frente a activos corrientes de 123,120 dólares.

Bespoke Extracts (OTCQB: BSPK)� 2025� 1분기 재무 결과와 전략� 리브랜딩 계획� 발표했습니다. 회사� 콜로라도 대마초 시장� 8.8% 축소� 상황에서� 매출 263,159달러� 기록하며 2024� 1분기 대� 1% 성장했습니다. 총이익은 전년 동기 대� 102,581달러에서 110,779달러� 개선되었�, 순손실은 314,118달러에서 260,521달러� 감소했습니다.

회사� 성공적으� The Joint Company (TJC)� 리브랜딩� 완료하고 � 가지 신제품인 Doobskis와 Dutch Blunts� 출시했습니다. 운영 효율화로 2024� 1분기 대� 일일 프리� 생산량이 32% 증가했습니다. 2025� 2분기 매출은 385,000달러� 초과� 것으� 예상되며, 이는 2024� 2분기 278,163달러보다 크게 증가� 수치입니�.

이러� 개선에도 불구하고, 회사� 2025� 3� 31� 기준 주주 결손� 2,334,200달러와 유동부� 1,241,535달러, 유동자산 123,120달러� 재정� 어려움� 직면� 있습니다.

Bespoke Extracts (OTCQB : BSPK) a publié ses résultats financiers du premier trimestre 2025 ainsi que ses initiatives stratégiques de rebranding. La société a réalisé un chiffre d’affaires de 263 159 dollars, soit une hausse de 1 % par rapport au premier trimestre 2024, malgré une contraction de 8,8 % du marché du cannabis au Colorado. Le bénéfice brut s’est amélioré, passant de 102 581 dollars à 110 779 dollars, tandis que la perte nette a diminué, passant de 314 118 dollars à 260 521 dollars.

L’entreprise a réussi son rebranding sous le nom de The Joint Company (TJC) et a lancé deux nouveaux produits : Doobskis et Dutch Blunts. Les améliorations opérationnelles ont conduit à une augmentation de 32 % de la production quotidienne de pré-roulés par rapport au premier trimestre 2024. Pour le deuxième trimestre 2025, la société prévoit un chiffre d’affaires supérieur à 385 000 dollars, nettement supérieur aux 278 163 dollars du deuxième trimestre 2024.

Malgré ces progrès, l’entreprise fait face à des défis financiers avec un déficit total des actionnaires de 2 334 200 dollars au 31 mars 2025 et des passifs courants de 1 241 535 dollars contre des actifs courants de 123 120 dollars.

Bespoke Extracts (OTCQB: BSPK) berichtete über die Finanzergebnisse des ersten Quartals 2025 und strategische Rebranding-Maßnahmen. Das Unternehmen erzielte einen Umsatz von 263.159 US-Dollar, eine Steigerung von 1 % gegenüber dem ersten Quartal 2024, trotz einer 8,8%igen Schrumpfung des Cannabis-Marktes in Colorado. Der Bruttogewinn verbesserte sich von 102.581 US-Dollar auf 110.779 US-Dollar, während der Nettoverlust von 314.118 US-Dollar auf 260.521 US-Dollar sank.

Das Unternehmen führte erfolgreich das Rebranding zu The Joint Company (TJC) durch und brachte zwei neue Produkte auf den Markt: Doobskis und Dutch Blunts. Operative Verbesserungen führten zu einer 32%igen Steigerung der täglichen Pre-Roll-Produktion im Vergleich zum ersten Quartal 2024. Für das zweite Quartal 2025 prognostiziert das Unternehmen einen Umsatz von über 385.000 US-Dollar, deutlich höher als die 278.163 US-Dollar im zweiten Quartal 2024.

Trotz dieser Verbesserungen steht das Unternehmen vor finanziellen Herausforderungen mit einem Gesamtkapitalfehlbetrag der Aktionäre von 2.334.200 US-Dollar zum 31. März 2025 sowie kurzfristigen Verbindlichkeiten von 1.241.535 US-Dollar gegenüber kurzfristigen Vermögenswerten von 123.120 US-Dollar.

Positive
  • None.
Negative
  • Significant stockholders' deficit of $2,334,200
  • Current liabilities ($1,241,535) substantially exceed current assets ($123,120)
  • Cash position decreased to $30,365 from $60,305
  • Accounts receivable declined to $36,757 from $57,276
  • Operating loss of $245,338 despite improved metrics

AURORA, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Bespoke Extracts, Inc. (OTCQB: BSPK), a Colorado based company focused on operating in the regulated cannabis markets in the United States, today announced its financial results for the first quarter ended March 31, 2025, and highlighted the successful rebranding of its product offerings under The Joint Company.

Financial Highlights for Q1 2025:

  • Revenue Growth: Sales increased to $263,159, up 1.0% from $260,428 in Q1 2024, fueled by strong direct sales of branded pre-rolled joints and expanded joint production services for licensed dispensaries in Colorado.

  • Improved Gross Profit: Gross profit rose to $110,779 from $102,581 in Q1 2024, driven by enhanced production efficiencies in pre-rolled joints, though partially offset by higher packaging and testing costs for new product launches.

  • Reduced Operating Expenses: Operating expenses fell to $356,117 from $405,384 in Q1 2024, reflecting lower stock-based compensation, reduced salaries, and decreased professional fees.

  • Reduced Net Loss: Net loss decreased to $260,521, from $314,118 in Q1 2024.

Strategic Rebranding and Product Expansion under The Joint Company (TJC)

In Q1 2025, Bespoke Extracts successfully rebranded as The Joint Company (TJC), a pivotal step in its growth strategy. TJC scaled its white-label processing business and launched two new branded products, Doobskis and Dutch Blunts, which have gained significant traction in Colorado’s regulated cannabis market. The Fresh Joint product line continues to increase product revenue, primarily through growth in multi-packs.

Operational Highlights:

  • Through its subsidiary, Bespoke Extracts Colorado, LLC, the Company operates a marijuana-infused products manufacturing facility in Aurora, selling its products and services to licensed dispensaries in Colorado.

  • Achieved cost efficiencies in raw materials, packaging, and labor, boosting gross margins despite increased marketing and sampling costs for new product launches.

  • Daily pre-roll production increased by 32% compared to Q1 2024, enhancing TJC’s ability to offer competitive processing services and lower priced products in Colorado.

  • The Company is exploring expansion of TJC into other state-regulated cannabis markets, leveraging its successful Colorado operations experience to pursue new growth opportunities.

  • Management is focused on expanding market share and optimizing operations for sustainable, long-term growth.

Management Commentary:

Michael Feinsod, CEO of Bespoke Extracts, stated: “Q1 2025 marked a transformative period for Bespoke Extracts as we rebranded to The Joint Company and introduced Doobskis and Dutch Blunts. These initiatives, combined with enhanced third-party processing capabilities, have significantly strengthened our market position and revenue potential. Despite an 8.8% contraction in Colorado’s regulated cannabis market during the quarter ending March 31, 2025 compared to Q1 2024, we achieved year-over-year growth. Our improved manufacturing processes are delivering strong results, and we expect continued gross margin improvements as we scale. We remain committed to disciplined financial management and strategic expansion in the regulated cannabis market.�

Fiscal Q2 2025 Outlook:

  • Revenue Growth: Based on preliminary Q2 2025 sales data, we have seen significant sales traction in our new product lines during the second quarter. The Company projects revenue exceeding $385,000 for the quarter ending June 30, 2025, compared to $278,163 in the quarter ended June 30, 2024, driven by continued growth of FreshJoints , strong demand for Doobskis and Dutch Blunts and expanded third-party processing services.

  • Operational Efficiencies: Continued improvements in manufacturing processes are expected to support higher production volumes and consistent product quality.

  • Gross Margin Improvement: Enhanced production efficiencies and cost management in raw materials, packaging, and labor are projected to drive higher gross margins, despite increased marketing investments for new product launches.

Balance Sheet
Condensed Consolidated Balance Sheets
(unaudited)
March 31,
2025
December 31,
2024
Assets
Current assets
Cash$ 30,365$ 60,305
Accounts receivable, net36,75757,276
Prepaid Expense17,09415,150
Inventory, net38,90432,526
Total current assets123,120165,257
Furniture and equipment29,55731,342
License10,00010,000
Right of Use Asset73,448140,489
Deposits12,00012,000
Total assets$ 248,125$ 359,088
Liabilities and Stockholders� (Deficit)
Current liabilities
Accounts payable and accrued liabilities$ 1,123,600$ 958,276
Note payable13,00020,000
Advances � related party66,87266,872
Operating lease liability38,06373,523
Total current liabilities1,241,5351,118,671
Long-Term Liabilities
Notes Payable � secured (net of discount )286,945241,351
Notes Payable169,000169,000
Note Payable � related party849,500849,500
Long-Term Operating Lease Liability35,34572,504
Total liabilities2,582,3252,451,026
Shareholders� Deficit
Series C Convertible Preferred Stock, 1 share issued and outstanding as of March 31,2025 and December 31, 2024--
Common stock, $0.001 par value: 3,000,000,000 authorized: 11,153,220 issued and outstanding as of March 31, 2025 and December 31, 202411,15111,151
Additional paid-in capital24,319,28624,301,027
Accumulated deficit(26,664,637)(26,404,116)
Total stockholders� deficit(2,334,200)(2,091,938)
Total liabilities and shareholders� deficit248,125359,088


Condensed Consolidated Statement of Operations
(Unaudited)
For the Three Months
Ended
March 31,
March 31,
2025
March 31,
024
Sales$ 263,159$ 260,428
Cost of products sold152,380157,847
Gross Profit110,779102,581
Operating expenses:
Selling, general and administrative expenses313,153347,859
Professional fees42,96457,525
Total operating expenses356,117405,384
Loss from Operations(245,338)(302,803)
Other income/(expenses)
Interest expense(15,183)(11,315)
Total other (expense)/income(15,183)(11,315)
Loss before income tax(260,521)(314,118)
Provision for income tax
Net Loss$ (260,521)$ (314,118)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic and Diluted11,153,22010,168,220
NET LOSS PER COMMON SHARE OUTSTANDING
Basic and Diluted$ (0.02)$ (0.03)

Forward-Looking Statements:

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

About Bespoke Extracts, Inc.:

Bespoke Extracts, Inc. is a Nevada corporation operating in the regulated cannabis markets in the United States. Through its wholly-owned subsidiary, Bespoke Extracts Colorado, LLC, the Company operates a marijuana-infused products manufacturing facility in Aurora, Colorado, focusing on delivering high-quality products to licensed dispensaries under its rebranded portfolio, The Joint Company.

Contact:

Bespoke Extracts, Inc.
Email: [email protected]
Website: www.bespokeextracts.com

Note: The financial data in this press release is derived from the Company’s unaudited consolidated financial statements included in its Form 10-Q for the quarter ended March 31, 2025, filed with the SEC. Forward-looking revenue projections and expansion plans are based on management’s current expectations and are subject to change.


FAQ

What were Bespoke Extracts (BSPK) Q1 2025 earnings results?

BSPK reported Q1 2025 revenue of $263,159 (up 1% YoY), gross profit of $110,779, and a net loss of $260,521 (improved from $314,118 in Q1 2024).

How much revenue is BSPK projecting for Q2 2025?

BSPK projects Q2 2025 revenue to exceed $385,000, compared to $278,163 in Q2 2024, driven by new product lines and expanded processing services.

What new products did Bespoke Extracts launch under The Joint Company rebranding?

Under The Joint Company rebranding, BSPK launched two new products: Doobskis and Dutch Blunts, while continuing to grow their Fresh Joint product line.

How did BSPK's operating expenses change in Q1 2025?

Operating expenses decreased to $356,117 from $405,384 in Q1 2024, due to lower stock-based compensation, reduced salaries, and decreased professional fees.

What is BSPK's current financial position as of March 31, 2025?

BSPK has current assets of $123,120, current liabilities of $1,241,535, and a stockholders' deficit of $2,334,200.

How much did BSPK's pre-roll production increase in Q1 2025?

BSPK reported a 32% increase in daily pre-roll production compared to Q1 2024, enhancing their ability to offer competitive processing services.
Bespoke Extracts

OTC:BSPK

BSPK Rankings

BSPK Latest News

BSPK Stock Data

704.12k
8.86M
20.16%
9.13%
Drug Manufacturers - Specialty & Generic
Healthcare
United States
Aurora